Dudy Aldiansyah
Universitas Prima Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Interleukin 6 Serum Level Between Menopausal Woman and Reproductive Woman Dalmy Iskandar; Fidel Ganis Siregar; Syamsul A. Nasution; M. Fauzie Sahil; Binarwan Halim; Dudy Aldiansyah
Vitamin : Jurnal ilmu Kesehatan Umum Vol. 4 No. 3 (2026): July : Jurnal ilmu Kesehatan Umum
Publisher : Asosiasi Riset Ilmu Kesehatan Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61132/vitamin.v4i3.2759

Abstract

Menopause is associated with declining estrogen levels and various symptoms that may affect women's quality of life. Interleukin-6 (IL-6), a pro-inflammatory cytokine influenced by estrogen, may serve as a potential biomarker for assessing the severity of menopausal symptoms. This study aimed to compare median serum IL-6 levels between postmenopausal and reproductive-age women and examine their differences according to the severity and types of menopausal symptoms. This analytical cross-sectional study involved 80 participants, comprising 40 postmenopausal women and 40 reproductive-age women. Participants completed the Menopause Rating Scale (MRS) questionnaire, and 3 mL of venous blood was collected to measure serum IL-6 levels at Prodia Clinic Laboratory. Data were analyzed using SPSS version 17 with ANOVA or the Kruskal–Wallis test, as appropriate. The median serum IL-6 level was higher in postmenopausal women than in reproductive-age women (1.70 vs. 1.37 pg/mL), although the difference was not statistically significant (p = 0.481). However, IL-6 levels differed significantly across the severity categories of menopausal symptoms (p < 0.0001), while no significant differences were found among the types of menopausal symptoms (p = 0.088). In conclusion, serum IL-6 levels did not differ significantly between postmenopausal and reproductive-age women but varied significantly according to the severity of menopausal symptoms. Further research is needed to clarify the potential role of IL-6 as a biomarker of menopausal symptom severity.